

Date: May 29, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 14/26-27	Our Reference No. 14/26-27

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting held on May 29, 2026

Pursuant to Regulations 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026, have approved:

- **Early retirement of Mr. Harish Kuber (ACS 10973) from the position of Company Secretary & Compliance Officer with effect from the close of business hours of May 29, 2026:**

The Board of Directors noted the early retirement of Mr. Harish Kuber, Company Secretary & Compliance Officer (Key Managerial Personnel) with effect from the close of business hours of May 29, 2026.

- **Appointment of Ms. Rashmi Khandelwal (ACS 28839) as the Company Secretary & Compliance Officer:**

On the recommendation of Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Ms. Rashmi Khandelwal (ACS A28839) as Company Secretary & Compliance Officer of the Company (Key Managerial Personnel) effective from May 30, 2026.

- **Appointment of Senior Management Personnel:**

Mr. Samir Kazi, Executive Vice President & Head Legal, Compliance & IP has been appointed as the Senior Management Personnel of the Company.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 along with letter

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

of resignation with respect to resignation of Company Secretary & Compliance Officer is enclosed herewith as **Annexure – I**, the details of appointment is enclosed herewith as **Annexure- II** and the details of appointment of Senior Management Personnel is enclosed herewith as **Annexure- III**.

The said Board Meeting commenced at 04:30 p.m. and ended at 7.26 p.m.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Anurag Mantri
Global Chief Financial Officer & Executive Director

Encl: As above

Annexure - I

Sr. No.	Particulars	Details
1.	Name and Designation	Mr. Harish Kuber Company Secretary & Compliance Officer (Key Managerial Personnel)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation
3.	Date of appointment/ cessation (as applicable) & terms of appointment	The resignation shall be effective from the close of May 29, 2026.
4.	Brief profile (in case of appointment)	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure - II

Sr. No.	Particulars	Details
1.	Name and Designation	Ms. Rashmi Khandelwal Company Secretary & Compliance Officer
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as Company Secretary & Compliance Officer (Key Managerial Personnel)
3.	Date of appointment/ cessation (as applicable) & terms of appointment	Appointment shall be effective from May 30, 2026
4.	Brief profile (in case of appointment)	<p>Ms. Rashmi Khandelwal is a qualified Company Secretary and legal professional with over 17 years of post-qualification experience in corporate governance, regulatory matters and strategic transactions across law firms, listed entities and regulated financial institutions.</p> <p>She holds a Bachelor's degree in Economics from the University of Delhi, a Bachelor of Laws (LLB), and a Post Graduate Diploma in Business Management (Finance).</p> <p>Ms. Rashmi Khandelwal is an experienced corporate governance and legal professional with diverse experience across Crompton Greaves Consumer Electricals Limited, ACC Limited, Yes Bank Limited, and Vaish Associates Advocates, with expertise in corporate governance, secretarial compliances, regulatory matters, corporate restructuring, stakeholder management, banking laws, legal and secretarial due diligence, and strategic transactions. She has handled diverse transactions and business structures including board and shareholder processes, Company Law matters, regulatory liaison, and governance transition in relation to the acquisition of ACC Limited and Ambuja Cements Limited by the Adani Group.</p> <p>During her professional tenure, organisations associated with her have received recognitions including the Golden Peacock Award for Corporate Governance and the Best Annual Report Award by the Free Press Journal. She also contributed to the development of GRI-aligned Integrated</p>

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

		<p>Annual Reports and strengthening ESG and governance frameworks.</p> <p>Ms. Khandelwal is regarded as a thought leader in corporate governance, known for combining legal rigor with practical business insight, and for strengthening governance, transparency, and regulatory credibility across organisations.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure - III

Sr. No.	Particulars	Details
1.	Name and Designation	Mr. Samir Kazi Executive Vice President & Head Legal, Compliance & IP
2.	Reason for change viz. appointment	Appointment as Senior Management Personnel
3.	Date of appointment (as applicable) & terms of appointment	With effect from May 29, 2026 Term of Appointment: Existing full time employment
4.	Brief profile (in case of appointment)	<p>Samir Kazi is a seasoned legal, compliance, and corporate governance leader with more than two decades of experience across the pharmaceutical, corporate, and consulting sectors. He currently serves as Executive Vice President and Head – Legal, Compliance & Intellectual Property at Glenmark Pharmaceuticals Limited where he oversees global legal strategy, ethics and compliance, intellectual property, risk management, litigation, and corporate governance initiatives. Prior to joining Glenmark, he held key leadership and advisory roles with organizations including Pfizer Limited, Hinduja Group India Pvt Ltd, and law firms such as Mulla & Mulla & Craigie Blunt & Caroe.</p> <p>Samir Kazi is recognized for driving strong governance frameworks and fostering ethical business culture. His leadership has contributed significantly to strengthening compliance systems and legal operations in highly regulated industries, particularly pharmaceuticals and healthcare. He has also been acknowledged within the legal fraternity for his contributions to in-house counsel excellence, including recognition in the LawWiser General Counsels Hall of Fame. Professionally, he is regarded as a strategic and business-oriented legal executive with a reputation for integrity, stakeholder management, crisis handling, and cross-functional leadership. His experience spans global operations, complex regulatory environments, and high-impact corporate decision-making.</p>

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

		Academically, he holds a Bachelor of Laws (LL.B.) degree and a Bachelor of Commerce degree specializing in Financial Accountancy and Taxation from University of Mumbai.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

May 29, 2026

To

The Board of Directors
Glenmark Pharmaceuticals Limited
Glenmark House,
B. D. Sawant Marg,
Off. Western Express Highway,
Mumbai - 400 099

Dear Sir,

Sub.: Early retirement from the position of Company Secretary & Compliance Officer of Glenmark Pharmaceuticals Limited ("the Company")

After an enriching journey of more than nine and half years with the Company, I have decided to take early retirement. I have decided to step down from my position as Company Secretary & Compliance Officer. Accordingly, I hereby submit my resignation, with effect from close of May 29, 2026. For smooth transition I am willing to continue in the employment of the Company for few months.

I am deeply grateful for the guidance and support of the Board members, my peers, my team and all other colleagues in the organization.

Request you to kindly take this on record and initiate necessary steps for filing the intimation with necessary authorities.

Thanking you,



Harish Kuber

Accepted
for my
29/05/26